Rome process


The Rome process and Rome criteria are an international effort to create scientific data to help in the diagnosis and treatment of functional gastrointestinal disorders, such as irritable bowel syndrome, functional dyspepsia and rumination syndrome. The Rome diagnostic criteria are set forth by Rome Foundation, a not for profit 501 organization based in Raleigh, North Carolina, United States.

History

Several systematic approaches attempted to classify functional gastrointestinal disorders. As a result, there were several key events which ultimately led to the current Rome Classification. In 1962, Chaudhary and Truelove published their study of IBS patients in Oxford, England. This was the first attempt to classify the new field of functional gastrointestinal disorders. Much of what they reported has persisted to the present day.
Subsequently, in 1978 came the "Manning Criteria" developed by Heaton and colleagues in Bristol. This characterized IBS-D, but importantly, a cluster of symptoms which were characteristic for this disorder. This ultimately became the basis for Rome's symptom-based criteria for IBS.
From 1980 to 1994, there were several epidemiological and clinical studies evaluating symptom prevalence and frequency in healthy subjects and IBS patients. Thompson, Drossman, Talley, Whitehead, and Kruis.
In 1989, the first consensus-based diagnostic criteria for IBS were established. The following year, a classification system for FGIDs was established.
From 1991 to 1993, several working teams published symptom-based criteria and clinical features of the functional GI disorders within these anatomic domains in Gastroenterology International.
In 1993, a validated questionnaire of all the diagnostic criteria was created and was then applied in a national survey, the US Householder Survey: the first national epidemiological database on the prevalence, demographic factors, and health care seeking features of people with FGIDs.
In 1994, FGIDs were categorized into anatomical domains and resulted in a book now recognized as Rome I – The Functional Gastrointestinal Disorders: Diagnosis, Pathophysiology and Treatment – A Multinational Consensus.
The Rome criteria have been evolving from the first set of criteria issued in 1989 through the Rome Classification System for functional gastrointestinal disorders, or Rome-1, the Rome I Criteria for IBS and the functional gastrointestinal disorders, the Rome II Criteria for IBS and the functional gastrointestinal disorders to the Rome III Criteria. "Rome II" and "Rome III" incorporated pediatric criteria to the consensus.
The Rome IV update was published 10 years later in May 2016. This covers epidemiology, pathophysiology, psychosocial and clinical features, and diagnostic evaluation and treatment recommendations for 33 adult and 17 pediatric functional gastrointestinal disorders.

Process

The Rome criteria are achieved and finally issued through a consensual process, using the Delphi method. The Rome Foundation process is an international effort to create scientific data to help in the diagnosis and treatment of functional gastrointestinal disorders, also known as disorders of gut-brain interaction. The Rome Diagnostic criteria are set forth by the Rome Foundation, an independent, not for profit 501 organization.

The Rome Foundation

The Rome Foundation, incorporated in 1996 and based in Raleigh, North Carolina, is an independent not for profit 501 3 organization. The foundation provides support for activities which foster clinical research, data and educational information which aid in the diagnosis and treatment of functional gastrointestinal disorders.
Over the last 25 years, the Rome organization has sought to legitimize and update the knowledge of functional GI disorders. This has been accomplished by bringing together scientists and clinicians from around the world to classify and critically appraise the science of gastrointestinal function and dysfunction. This knowledge permits clinical scientists to make recommendations for diagnosis and treatment that can be applied in research and clinical practice. The mission is to improve the lives of people with these disorders.
The goals of the Rome Foundation are to promote global recognition and legitimization of FGIDs, advance the scientific understanding of their pathophysiology, optimize clinical management for these patients and develop and provide educational resources to accomplish these goals.

Definition of functional gastrointestinal disorders/disorders of gut-brain interaction

Using the Delphi method, the Rome Foundation and its board of directors, chairs and co-chairs of the ROME IV committees developed the current definition for disorders of gut-brain interaction.
A group of disorders classified by GI symptoms related to any combination of:

Rome I

In 1994, Rome I was published as The Functional Gastrointestinal Disorders:Diagnosis, Pathophysiology, and Treatment—A Multinational Consensus.

Rome II

By the mid-1990s, the concept of FGID classification and the use of diagnostic criteria was promoted due to the US Food and Drug Administration recommended the use of the IBS criteria for selection into pharmaceutical studies, and the pharmaceutical companies took interest in supporting the efforts of the Rome Foundation to improve the understanding, diagnosis, and treatment of FGIDs and to also apply the use of these criteria in their pharmaceutical studies. In Rome II, the pediatric population of FGIDs was added.

Rome III

After publication of Rome II, the number of studies published using the Rome criteria in clinical trials grew tremendously over the next 15 years. Rome III differed from Rome I and II by the use of more evidence-based rather than consensus-based data.

Rome IV

After publication of Rome III in 2006, the Rome Foundation was well recognized as the authoritative body developing diagnostic criteria for research and also for providing education about the FGIDs. Rome IV tried to address the limitations of a symptom-based criteria in several ways:
  1. To address the severity and variability of clinical presentation, a Multidimensional Clinical Profile system has been created that incorporates the diagnostic criteria with additional clinical, quality of life, psychosocial, and physiological parameters to more precisely create an individualized treatment plan for the patient.
In Rome IV, the classification moved from a physiologically based classification to a symptom-based classification. The classifications were based upon organ regions.

Rome IV criteria/classification

The original Rome classification was first published in 1990 and has since been modified with each iteration to develop the subsequent classifications with Rome II, III and IV. Beginning with the original publication in 1990 and leading to Rome I, the classification moved from a physiologically based classification to a symptom-based classification with additional classifications based upon organ regions. The current Rome IV classification is the culmination of the evolution of a series of iterations with its inception as Rome I.
The Rome criteria are a set of criteria used by clinicians to classify a diagnosis of a patient with an FGID. These Rome criteria are updated every 6–10 years.
The current Rome IV classification, published in 2016, is as follows:
A. Esophageal Disorders
B. Gastroduodenal Disorders
C. Bowel Disorders
D. Centrally Mediated Disorders of Gastrointestinal Pain
E. Gallbladder and Sphincter of Oddi disorders
F. Anorectal Disorders
G. Childhood Functional GI Disorders: Neonate/Toddler
H. Childhood Functional GI Disorders: Child/Adolescent
FGIDs share in common any of several physiological features including increased motor reactivity, enhanced visceral hypersensitivity, altered mucosal immune and inflammatory function, and altered central nervous system and enteric nervous system regulation.

Pathophysiology

The pathophysiology of FGID has been best conceptualized using biopsychosocial model help to explain the relationships between an individual factors in their early life that intern can influence their psychosocial factor and physiological functioning. This model also shows the complex interactions between these factors through the brain-gut axis. These factors affect how FGID manifest in terms of symptoms but also affect the clinical outcome. These factors are interconnected and the influences on these factors are bidirectional and mutually interactive.

Early life factors

Early life factors include genetic factors, psychophysiological and sociocultural factors, and environmental exposures.
Psychosocial factors influence the functioning of the GI tract through the brain-gut axis. They also affect experience and behavior, treatment selection and the clinical outcome. Psychological stress or one's emotional response to stress exacerbates gastrointestinal symptoms and may contribute to FGID development.

Physiology

The physiology of FGID is characterized by abnormal motility, visceral hypersensitivity as well as dysregulation of the immune system and barrier function of the GI tract as well as inflammatory changes.
There has been increased attention to the role of bacteria and the microbiome in overall health and disease. There is evidence for a group of microorganisms which play a role in the brain-gut axis. Studies have revealed that the bacterial composition of the gastrointestinal tract in IBS patient differs from healthy individuals However, further research is needed to determine the role of the microbiome in FGIDs.
The brain-gut axis is the mechanism in which the psychosocial factors influence the GI tract and vice versa. There is communication between emotional and cognitive centers of the brain to the GI tract and vice versa. Emotions have been shown to stimulate colon motor function and result in decreased colonic transit time, increased contractile activity, the induction of defecation, and symptoms of diarrhea.